Compare TG Therapeutics Inc (TGTX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Waste Management, Inc. — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Waste Management, Inc. trades at $217.2 (market cap $87.05B). The key difference: Waste Management, Inc. is far larger — about 10.2× TG Therapeutics Inc's market cap, and Waste Management, Inc. pays a 1.74% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WM | |
|---|---|---|
Market Cap | $8.53B | $87.05B |
Sector | Health | Industrials |
52-Week High | $59.06 | $246.51 |
52-Week Low | $26.94 | $196.77 |
Enterprise Value | $8.74B | $109.85B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
WM trades at $217.78, down 0.55% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing Q4 2025. Revenue grew to $25.20B in 2025, with strong profitability margins. Analysts maintain a buy consensus with a $263.43 price target, though technical indicators show near-term pressure.
The outlook is supported by steady waste-service demand and sustainability investments, but high debt levels and valuation concerns pose risks. CEO transition adds uncertainty, while institutional buying signals confidence. Upside exists if execution aligns with analyst targets, but investors should weigh premium valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
